Rituxan added to CHOP of benefit in Richter's Syndrome

[Guest guest]

5 year study from Japan looking at Richter's Transformations ( CD5+ DLBCL )

indicates that rituximab is of benefit to the CHOP treatment.

Both the complete response rate and overall survival (OS) were significantly

better in the rituxan + chemotherapy group than in the 'chemotherapy only'

group.

However central nervous system relapses were the same for each arm of the

clinical trials.

The study concludes that: " Despite the use of rituximab, the 2-year OS of CD5+

DLBCL remains poor (70%). As CD5+ DLBCL is complicated by a high incidence of

CNS relapse, a more effective therapeutic strategy with CNS prophylaxis is

needed " .

Source: ls of Oncology, Jan 2011 : doi: 10.1093/annonc/mdq627

http://annonc.oxfordjournals.org/content/current

~chris

CLL CANADA

http:/cllcanada.ca